An interventional study of Autologous Platelet-Rich Plasma (A-PRP) Injection and Transobturator Tape (TOT) Procedure in Urinary Incontinence, Stress, sponsored by Benha University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Benha University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Urinary Incontinence, Stress with a site in Egypt — 15 open to participants now, 19 under way, none of them phase 3. Urinary Incontinence, Stress · Egypt.
Among the 40 studies in Urinary Incontinence, Stress with a site in Egypt, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2025, is one of 24 with no phase, and was the 40th registered.
655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.
Browse Urinary Incontinence, Stress studies →15 of the 40 studies in Urinary Incontinence, Stress with a site in Egypt are open now. Recruiting first, the newest first:
Benha University · Sites in Egypt
Ages 18+ · Women only
Benha University · Sites in Egypt
Ages 50–65 · Women only · Healthy volunteers
Al-Azhar University · Sites in Egypt
Ages 20–45 · Women only
Cairo University · Sites in Egypt
Ages 40–60 · Women only
Cairo University · Sites in Egypt
Ages 18–65 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2014; this study’s year is marked. 6 started in 2025.
This study's enrollment of 80 is above the median of 68 across 510 interventional studies indexed under Urinary Incontinence, Stress.
Median enrollment 60 across the 32 interventional studies, 122 across the 8 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 40 have an industry lead sponsor. The 10 most frequent:
Benha University is the lead sponsor of 365 studies on the registry; 67 are open to participants now.
Benha University has 5 studies filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
4 of the studies in Urinary Incontinence, Stress with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661264Cairo UniversityEffect of Different Pelvic Floor Loading Techniques on Women With Stress Urinary Incontinence | 2026-12-15 |
| NCT07762300Benha UniversityHybrid Transobturator Tape Versus Conventional Synthetic Tape for Stress Urinary Incontinence | 2027-03-01 |
| NCT07807982Benha UniversityPeri-Urethral Platelet-Rich Plasma Injections for Postmenopausal Female Stress Urinary Incontinence | 2027-03-15 |
| NCT07550426Ain Shams UniversityThe Effect of Periurethral Injection of Platelet Rich Plasma Versus Mid-urethral Sling in Treatment of Stress Urinary Incontinence | 2027-04-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Urinary Incontinence, Stress with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aimed to compare the effectiveness and safety of autologous platelet-rich plasma (A-PRP) injections and transobturator tape (TOT) surgery for treating stress urinary incontinence in women.
This prospective, randomized, parallel-group clinical trial included 80 women aged 18-65 years with confirmed stress urinary incontinence. Participants were randomly assigned to receive either A-PRP injections or TOT surgery, with 40 women in each group.
Participants were assessed before treatment and at 3 and 6 months after treatment. The primary outcome was the objective cure rate at 6 months, assessed using a standardized stress test. Secondary outcomes included urinary symptoms, quality of life, urine leakage, urodynamic measurements, adverse events, and the need for additional treatment.
The study was conducted at a tertiary-care academic institution in Egypt between June 2025 and June 2026.
Stress urinary incontinence (SUI) is a common condition in women, characterized by involuntary urine leakage during activities that increase intra-abdominal pressure, such as coughing, sneezing, or physical exertion. It can significantly affect quality of life and daily activities.
Transobturator tape (TOT) is an established surgical treatment for SUI that provides support to the mid-urethra. However, surgical treatment may be associated with complications, including mesh-related adverse events.
Autologous platelet-rich plasma (A-PRP) is a minimally invasive regenerative treatment obtained from the patient's own blood. It contains concentrated platelets and growth factors that may promote tissue repair and improve urethral support.
This prospective, randomized, parallel-group comparative trial evaluated the efficacy and safety of A-PRP injections versus TOT surgery in 80 women aged 18-65 years with urodynamically confirmed SUI.
Eligible participants were randomly allocated in a 1:1 ratio to two treatment groups. The A-PRP group received a transvaginal injection of approximately 5 mL of autologous platelet-rich plasma into the anterior vaginal wall at three periurethral sites. The TOT group underwent an outside-in transobturator mid-urethral sling procedure using polypropylene mesh tape.
Clinical outcomes were assessed at baseline and at 3 and 6 months after treatment. The primary outcome was objective cure at 6 months, defined by a negative standardized stress test in the absence of symptomatic SUI.
Secondary outcomes included changes in International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), Urogenital Distress Inventory-6 (UDI-6), and Incontinence Quality of Life (I-QOL) scores, 24-hour pad test results, urodynamic parameters, adverse events, and the need for additional treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Symptomatic stress urinary incontinence for at least 6 months.
Positive stress test.
Urodynamically confirmed stress urinary incontinence without evidence of detrusor overactivity.
Willingness and ability to comply with the study protocol and follow-up schedule.
Exclusion Criteria:
Recurrent stress urinary incontinence following previous anti-incontinence surgery.
Active urinary tract infection.
Moderate to severe pelvic organ prolapse (POP-Q stage II or higher).
Significant cardiac or pulmonary comorbidity rendering the patient unfit for general or regional anesthesia.
Known coagulopathy or bleeding diathesis.
Uncontrolled diabetes mellitus ( > 8.5%).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group received a transvaginal injection of approximately 5 mL of autologous platelet-rich plasma (A-PRP) into the anterior vaginal wall at three periurethral sites, approximately 1 cm proximal to the urethral meatus. The procedure was performed under local anesthesia using 2% lidocaine gel.
Procedure: Autologous Platelet-Rich Plasma (A-PRP) Injection
Participants in this group underwent a transobturator tape (TOT) procedure using a polypropylene monofilament mid-urethral sling inserted through an outside-in transobturator approach under spinal or general anesthesia. The tape was positioned tension-free beneath the mid-urethra.
Procedure: Transobturator Tape (TOT) Procedure
Approximately 15 mL of autologous venous blood was collected and centrifuged at 1,500 rpm for five minutes to obtain approximately 5 mL of platelet-rich plasma. The A-PRP was injected transvaginally into the anterior vaginal wall at three periurethral sites, approximately 1 cm proximal to the urethral meatus, using a 27-gauge needle under local anesthesia with 2% lidocaine gel.
Participants underwent an outside-in transobturator mid-urethral sling procedure using polypropylene monofilament mesh tape under spinal or general anesthesia. The tape was positioned tension-free beneath the mid-urethra, and intraoperative cystoscopy was performed to exclude bladder or urethral perforation.
Objective Cure Rate at 6 Months
The proportion of participants achieving objective cure, defined as a negative standardized cough stress test in the absence of symptomatic stress urinary incontinence. The test was performed with a comfortably full bladder (at least 200 mL) in the lithotomy position. Urine leakage observed during coughing was considered a positive test.
Time frame: 6 months after intervention
Change in ICIQ-UI SF Score
Change from baseline in the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) total score. Scores range from 0 to 21, with higher scores indicating more severe urinary incontinence symptoms.
Time frame: Baseline, 3 months, and 6 months after intervention
Change in 24-Hour Pad Test Weight
Change from baseline in urine leakage measured using a 24-hour pad test. Participants wore pre-weighed continence pads for 24 hours, and urine loss was determined from the change in pad weight in grams, corrected for evaporation.
Time frame: Baseline, 3 months, and 6 months after intervention
Change in Maximum Urethral Closure Pressure
Change from baseline in maximum urethral closure pressure (MUCP), measured in cmH2O using multichannel urodynamic testing.
Time frame: Baseline and 6 months after intervention
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jun 2026, 12 months.
Of 227 non-industry interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 12 months is below that.
Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urinary Incontinence, Stress →